MicroRNAs As Targets for Anti-Angiogenic Therapies

Case ID:
C05032
C05032: MicroRNAs As Targets for Anti-Angiogenic Therapies
Technical Details:
MicroRNAs (miRNAs) are 18-24 nucleotide RNA molecules that regulate the stability or translational efficiency of target mRNAs. miRNAs are frequently dysregulated in cancer cells and can act as oncogenes and tumor-suppressors. The proto-oncogene c-MYC encodes a transcription factor that regulates cell proliferation, growth, and apoptosis. Dysregulated expression or function of c-Myc is one of the most common abnormalities in human malignancy. The MYC cancer gene increases the expression of a cluster of miRNAs that are implicated in the development of human cancers. Scientists at JHU and the University of Pennsylvania have now demonstrated that the MYC-activated miRNAs promote angiogenesis and thus promote tumor growth
Looking for Partners:
These microRNAs represent a novel class of targets for anti-angiogenesis therapies.
Publications:
Nature Genetics - 38, 1060 - 1065 (2006); US 9,255,267; and US 8,466,117 
 
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster PCT: Patent Cooperation Treaty United States 12/309,788 8,466,117 3/15/2010 6/18/2013 7/28/2027 Granted
Compositions and Methods for Modulating Angiogenesis CON: Continuation United States 13/919,417 9,255,267 6/17/2013 2/9/2016 7/30/2027 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Michael Woods
mwoods19@jh.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum